Researchers have engineered mice that model the switch from fetal to adult hemoglobin, an important step towards curing genetic blood diseases such as sickle cell anemia and beta-thalassemia.

SCD gene therapy approaches using CRISPR, gene therapy, and base editing show different stem cell outcomes in a mouse study.

PHILADELPHIA, June 1, 2021 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and ...

Can we predict that natural selection will weed out genetic disease over time? Sickle-cell trait haplotype distribution shows the genetic advantages of this mutation. In the deoxygenated environment ...

Please provide your email address to receive an email when new articles are posted on . The inactivation of the BCL11A gene allowed for the increased expression of gamma-globin (the fetal form of ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or “bluebird”) today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data ...